Merck & Co doubles up on Ablynx research deal


Cut-down antibody drug developer Ablynx has agreed a second R&D partnership with US Pharma firm Merck & Co. Ablynx will receive €20 million (£17 million) up front, plus up to €10.7 million in research funding over three years. On top of that, milestone payments for any products that emerge from the collaboration could net the Belgian biotech up to €1.7 billion plus royalties.

This collaboration will focus on nanobodies (antibody fragments) directed against cancer, and builds on Merck’s previous collaboration with Ablynx for nanobodies that target voltage-gated ion channels. Ablynx also recently joined forces with Abbvie to develop nanobodies for treating rheumatoid arthritis and systemic lupus erythematosus.


Related Content

Grabbing slices of the immuno-oncology pie

5 August 2015 Business

news image

Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’

Merck & Co $460m ion channel deal

2 October 2012 Business

news image

Deal with Ablynx relates to antibody fragments

Most Commented

Rechargeable first for promising battery tech

6 May 2016 Research

news image

New cathode material makes for energetic, rechargeable sodium–carbon dioxide batteries that could power Mars vehicles

WHO clarifies glyphosate risks

23 May 2016 Business

news image

UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels